CytomX Therapeutics Reports FY Revenue Miss, Falling $7.3M Short of Estimates
Summary
CytomX Therapeutics reported full-year revenue of $76.201 million, significantly missing analyst estimates of $83.5 million by $7.3 million, an approximately 8.7% shortfall. This revenue miss, coupled with a reported net loss of $17.368 million and negative operating income, indicates a weaker financial performance than anticipated. The news follows recent analyst expectations of a substantial decline in Q4 2025 revenue, confirming a challenging period for the company. For a company trading near its 52-week high, this material miss could lead to negative investor sentiment and pressure on the stock price. Traders will be closely watching for management's explanation for the miss and any updated guidance.
At the time of this announcement, CTMX was trading at $6.56 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $793M. The 52-week trading range was $0.40 to $6.35. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.